GMP Storage Market

GMP Storage Market Analysis and Forecast by Fact.MR

The GMP storage market, valued at USD 5.21 billion in 2025, is expanding at a 5.0% CAGR to reach USD 8.911 billion by 2036. GMP (Good Manufacturing Practice) storage encompasses temperature-controlled warehousing, ambient storage, and ultra-low frozen storage facilities that comply with pharmaceutical regulatory requirements for storing drugs, biologics, clinical trial materials, medical devices, and raw materials. Growth reflects the expanding global biopharmaceutical production base, increasing clinical trial activity, and tightening cold chain integrity requirements for biologics and cell/gene therapies. The USD 3.44 billion incremental opportunity between 2026 and 2036 is concentrated in cold and ultra-low storage for biologics across Asia, North America, and Europe.

Summary of GMP Storage Market

• Market Snapshot
  • Market value in 2025: USD 5.21 billion
  • Projected value in 2026: USD 5.471 billion; forecast to reach USD 8.911 billion by 2036
  • CAGR from 2026 to 2036: 5.0%
  • Incremental opportunity (2026 to 2036): USD 3.44 billion
  • Cold storage leads facility type demand with 50.0% share in 2025
  • India and China lead country-level growth, followed by Brazil and Germany
• Demand and Growth Drivers
  • The biopharmaceutical industry is producing an expanding portfolio of temperature-sensitive biologics, biosimilars, and cell/gene therapies that require validated GMP cold chain storage from manufacturing through distribution.
  • Clinical trial activity is increasing globally, with each trial requiring GMP-compliant storage for investigational products, comparator drugs, and biological samples throughout the study period.
  • Regulatory inspections and audit requirements are tightening worldwide, mandating validated storage conditions with continuous temperature monitoring, deviation management, and documented quality systems.
  • Pharmaceutical companies are outsourcing storage to specialized third-party logistics providers to reduce capital expenditure and access validated GMP storage capacity without self-build investment.
• Product and Segment View
  • Cold storage holds 50.0% of facility type demand, driven by the growing proportion of temperature-sensitive biologics requiring 2 to 8 degrees C storage.
  • Biopharma accounts for 55.0% of end-user demand, reflecting the concentration of GMP storage requirements in biologic drug product and substance storage.
  • Pharmaceutical storage holds 45.2% of application share, covering finished drug product storage under validated GMP conditions.
  • Key segmentation includes:
    • Facility Type: Cold Storage, Ambient Storage, Frozen Ultra Low
    • End User: Biopharma, CRO/CMO, Hospitals/Clinical
    • Application: Pharmaceutical Storage, Biologics Storage, Clinical Trial Storage, Medical Device Storage, Raw Material Storage
    • Distribution Channel: Direct Contracts, Third Party Logistics, Digital Platforms
• Geography and Competitive Outlook
  • North America is the largest revenue region, with the USA contributing USD 2.023 billion in 2025.
  • South Asia is the fastest-growing region, with India recording the highest country CAGR driven by biopharmaceutical manufacturing expansion.
  • Europe maintains strong growth, with Germany leading through pharmaceutical manufacturing density.
  • Thermo Fisher Scientific Inc. leads the competitive field with a 25.0% market share, followed by Lonza Group, WuXi AppTec, and Catalent.
• Analyst Opinion
  • The GMP storage market is an infrastructure category where growth is tied to the expanding volume and complexity of pharmaceutical products requiring validated storage conditions. The shift toward biologics, cell therapies, and mRNA-based products is increasing the proportion of the pharmaceutical portfolio requiring cold and ultra-low storage, creating capacity demand that exceeds ambient storage growth rates. Fact.MR expects the fastest growth in ultra-low frozen storage for cell/gene therapy materials and in cold storage expansion across India and China, where biopharmaceutical manufacturing capacity is scaling rapidly. The outsourcing trend toward third-party GMP logistics providers is creating a commercial model where storage capacity is purchased as a service rather than built as owned infrastructure.

Key Growth Drivers, Constraints, and Opportunities

Key Factors Driving Growth

• Biologics portfolio growth: The expanding global portfolio of biologic drugs requiring 2 to 8 degrees C storage creates proportional cold chain storage demand that grows with each new product approval and market entry.
• Clinical trial material storage: Increasing global clinical trial activity, particularly multi-center international trials, generates distributed GMP storage requirements across multiple countries and regions.
• Regulatory tightening: FDA, EMA, and other regulatory agencies are increasing inspection frequency and data integrity requirements for pharmaceutical storage facilities, driving investment in validated storage systems.

Key Market Constraints

• Capital intensity: GMP-compliant cold storage facility construction requires significant capital investment in temperature control, monitoring systems, backup power, and regulatory validation.
• Energy costs: Cold and ultra-low storage facilities consume substantial energy for continuous temperature maintenance, creating operating cost pressure that is amplified by energy price volatility.
• Regulatory complexity: Storage facilities must maintain compliance across multiple regulatory jurisdictions with varying GMP requirements, creating compliance management complexity for global storage operations.

Key Opportunity Areas

• Cell/gene therapy storage: The emergence of cell and gene therapies requiring ultra-low (minus 80 degrees C) and cryogenic storage creates a premium storage tier with high per-unit pricing and specialized infrastructure requirements.
• Emerging market storage capacity: Biopharmaceutical manufacturing expansion in India, China, and Southeast Asia is creating demand for local GMP storage infrastructure that currently requires import from established markets.
• Digital storage management: IoT-connected monitoring, blockchain-based chain of custody documentation, and predictive analytics for storage condition management are creating technology-differentiated service offerings.

Segment-wise Analysis of the GMP Storage Market

• Cold storage leads facility type demand at 50.0%, driven by biologic product storage requirements.
• Biopharma holds 55.0% of end-user share, reflecting the concentration of GMP storage in biologic drug storage.
• Pharmaceutical storage accounts for 45.2% of application demand.

Which facility type dominates the GMP Storage Market?

Cold storage holds a 50.0% share of facility type demand in 2025. The share reflects the growing proportion of pharmaceutical products requiring 2 to 8 degrees C storage, driven by the expanding biologics portfolio. Cold storage facilities require continuous temperature monitoring, validated HVAC systems, backup power infrastructure, and regulatory documentation that create higher capital and operating costs than ambient alternatives.

Ambient storage accounts for the second-largest share, serving stable pharmaceutical products, medical devices, and raw materials that do not require refrigeration. Ultra-low and frozen storage is the fastest-growing segment, driven by cell/gene therapy materials.

Which end user dominates the GMP Storage Market?

Biopharma accounts for 55.0% of end-user demand. Biopharmaceutical companies require validated GMP storage for drug substances, drug products, reference standards, and stability samples throughout product lifecycles. The outsourcing trend is shifting biopharma storage from owned warehouses to third-party providers that offer flexible capacity.

CRO/CMO organizations represent the second-largest end user, managing clinical trial material storage and contract manufacturing intermediate storage. Hospitals and clinical settings contribute a smaller share for investigational product storage.

Which application dominates the GMP Storage Market?

Pharmaceutical storage holds 45.2% of application demand. This category covers finished drug product storage under validated conditions, including temperature-controlled warehousing between manufacturing and distribution. The volume of pharmaceutical products requiring GMP storage grows proportionally with global pharmaceutical production output.

Biologics storage is the fastest-growing application, driven by the temperature sensitivity of monoclonal antibodies, vaccines, and cell/gene therapy products. Clinical trial storage is a specialized application requiring multi-country storage coordination.

Which Product Trend is Shaping the Next Phase of Growth in the GMP Storage Market?

Cell and gene therapy storage requirements are shaping the next capacity investment phase. Cell therapies (CAR-T, TCR-T) and gene therapies require ultra-low storage at minus 80 degrees C or cryogenic storage in liquid nitrogen, creating specialized infrastructure requirements that exceed conventional pharmaceutical cold chain capability. Each cell therapy product lot requires patient-specific storage with chain of custody documentation, creating per-patient storage demand at manufacturing, transit, and clinical sites. The commercial expansion of approved cell therapies (Kymriah, Yescarta, Abecma) and gene therapies is generating growing demand for ultra-low storage capacity.

The outsourcing of GMP storage to specialized third-party logistics providers is accelerating as pharmaceutical companies seek to reduce fixed infrastructure costs and access validated capacity on demand. Providers including DHL Life Sciences, Cryoport, and Marken are expanding GMP cold chain storage networks across North America, Europe, and Asia to serve multinational pharmaceutical clients. Fact.MR projects that third-party GMP storage will grow faster than in-house storage, reaching over 40% of total GMP storage capacity by 2036 as pharmaceutical companies optimize asset-light supply chain models.

Regional Outlook Across Key Markets

• North America is the largest revenue region, with the USA contributing USD 2.023 billion in 2025.
• South Asia is the fastest-growing region, with India recording the highest country CAGR.
• East Asia records strong growth, with China expanding biopharmaceutical manufacturing capacity.
• Europe maintains steady growth, shaped by pharmaceutical manufacturing density.

CAGR Table

Source: Fact.MR analysis, based on proprietary forecasting model and primary research.

India: biopharmaceutical manufacturing and storage capacity gap

India records the highest country-level CAGR driven by rapid biopharmaceutical and vaccine manufacturing expansion that is creating demand for GMP storage infrastructure. The country is a major vaccine producer and biosimilar manufacturer, and the growth of contract manufacturing for global pharmaceutical companies is generating storage requirements that exceed existing capacity. The government Pharma Vision 2030 initiative is supporting pharmaceutical infrastructure development.

• Growth anchor: Biopharmaceutical manufacturing expansion is creating GMP storage capacity demand that exceeds current infrastructure.

USA: biologics portfolio and cell therapy storage demand

The USA contributes USD 2.023 billion in 2025. Growth reflects the concentration of biologic drug production, cell/gene therapy manufacturing, and clinical trial activity that generates ongoing GMP storage demand. The expansion of ultra-low storage capacity for cell therapy products is a near-term investment priority for storage providers. Third-party GMP logistics providers are expanding US cold chain capacity.

• Growth anchor: Biologics production growth and cell/gene therapy storage requirements drive capacity investment.

China: biopharmaceutical scale-up and cold chain modernization

China records strong growth driven by the rapid scale-up of domestic biopharmaceutical manufacturing, the expansion of clinical trial activity under NMPA modernization, and government investment in pharmaceutical cold chain infrastructure. Chinese biopharmaceutical companies are building GMP storage capacity both domestically and internationally.

• Growth anchor: Biopharmaceutical manufacturing scale-up and cold chain modernization create structured storage demand.

Germany: pharmaceutical manufacturing hub

Germany leads European GMP storage growth supported by its position as a major pharmaceutical and biopharmaceutical manufacturing hub. The concentration of drug substance and drug product manufacturing creates co-located GMP storage demand. German 3PL providers serve as European distribution hubs for multinational pharmaceutical companies.

• Growth anchor: Manufacturing hub concentration and European distribution role create steady storage demand.

Competitive Benchmarking and Company Positioning

GMP Storage Market Analysis By Company

• Thermo Fisher Scientific leads with 25.0% market share, leveraging its integrated pharmaceutical services portfolio including storage, distribution, and clinical trial logistics through its Fisher BioServices and Patheon divisions.
• Lonza Group and WuXi AppTec compete in the CDMO-linked storage tier, where manufacturing and storage services are bundled within contract manufacturing relationships.
• DHL Life Sciences, Cryoport, and Marken maintain positions as specialized pharmaceutical third-party logistics providers offering GMP storage as a service across global networks.

The competitive field combines integrated pharmaceutical services companies (Thermo Fisher, Catalent), CDMOs with co-located storage (Lonza, WuXi AppTec, Samsung Biologics), and specialized pharmaceutical 3PL providers (DHL Life Sciences, Cryoport, Marken). Thermo Fisher leads through its integrated platform approach.

Competition in the 3PL tier is intensifying as pharmaceutical cold chain logistics providers invest in GMP storage capacity expansion across major pharmaceutical manufacturing corridors. Cryoport has emerged as a specialist in cell/gene therapy cold chain, commanding premium pricing for ultra-low and cryogenic storage services.

Regional storage providers in India and China are gaining share by offering GMP-compliant storage at cost points below multinational providers, serving domestic pharmaceutical manufacturers and contract research organizations.

Key Companies in the GMP Storage Market

Thermo Fisher Scientific Inc., Lonza Group AG, WuXi AppTec, Catalent Inc., Samsung Biologics, Charles River Laboratories, DHL Life Sciences, Cryoport Inc., Marken Ltd., and BioLife Solutions Inc. are the principal companies operating in the global GMP storage market.

Recent Industry Developments

• Thermo Fisher: GMP cold storage capacity expansion (2025)
  • Thermo Fisher Scientific expanded its GMP cold storage capacity in 2025, commissioning new temperature-controlled warehouse facilities in the USA and Singapore to serve growing biopharmaceutical client demand.
• Cryoport: cell therapy storage network expansion (2025)
  • Cryoport expanded its ultra-low temperature storage network in 2025, adding cryogenic storage capacity at facilities across North America, Europe, and Asia to serve the growing cell and gene therapy manufacturing and distribution market.
• DHL Life Sciences: India GMP storage facility commissioning (2025)
  • DHL Life Sciences commissioned a new GMP-compliant pharmaceutical storage facility in India in 2025, targeting the growing storage demand from Indian biopharmaceutical manufacturers and multinational companies with Indian manufacturing operations.
• Samsung Biologics: integrated CDMO storage expansion (2026)
  • Samsung Biologics expanded integrated GMP storage capacity at its Incheon manufacturing campus in early 2026, co-locating cold chain storage with biologic drug substance and drug product manufacturing lines.

Leading Companies Shaping the GMP Storage Market

• Global Players

  • Thermo Fisher Scientific Inc.
  • Lonza Group AG
  • WuXi AppTec
  • Catalent, Inc.
  • Samsung Biologics
  • Charles River Laboratories

• Regional Players

  • DHL Life Sciences
  • Cryoport, Inc.
  • Marken Ltd.
  • BioLife Solutions, Inc.

• Emerging / Start-up Players

  • FedEx Life Sciences
  • UPS Healthcare
  • Biostor

Sources and Research References

• Thermo Fisher Scientific Annual Report 2024 and Pharma Services Division Presentations
• Lonza Group Annual Report 2024
• FDA GMP Inspection and Compliance Reports
• EMA GMP Guidelines for Storage and Distribution
• Cryoport Inc. Annual Report 2024
• DHL Life Sciences Global Network Documentation

All numerical data in this report is derived from Fact.MR proprietary research. Source references are provided for contextual and directional validation only.

Key Questions This Report Addresses

• What is the projected size of the GMP storage market by 2036?
• Which facility type holds the largest share?
• What CAGR is expected from 2026 to 2036?
• Which country is growing fastest?
• Who is the leading company?
• What is the incremental opportunity between 2026 and 2036?
• How is cell/gene therapy affecting storage demand?
• What role does outsourcing play in GMP storage growth?

GMP Storage Market Definition

The GMP storage market covers regulatory-compliant warehousing and storage facilities that maintain pharmaceutical products, biologics, clinical trial materials, and raw materials under validated temperature and environmental conditions in accordance with Good Manufacturing Practice requirements.

GMP Storage Market Inclusions

• Cold storage facilities (2 to 8 degrees C) for biologics and temperature-sensitive pharmaceuticals
• Ambient storage (15 to 25 degrees C) for stable pharmaceutical products and medical devices
• Ultra-low and frozen storage (minus 20 to minus 80 degrees C) for cell/gene therapy materials and biological samples
• Clinical trial material storage services provided by CROs, CMOs, and third-party logistics providers

GMP Storage Market Exclusions

• Pharmaceutical manufacturing equipment and production facilities
• Drug distribution and last-mile delivery logistics
• Laboratory storage equipment (freezers, refrigerators) as capital goods
• Non-pharmaceutical cold chain storage (food, industrial)

GMP Storage Market Research Methodology

• Bottom-up revenue modeling using GMP storage capacity data, storage pricing per pallet/volume, and pharmaceutical production volumes across 15+ countries
• Primary interviews with pharmaceutical supply chain directors, GMP warehouse operators, and third-party logistics providers
• Cross-referencing pharmaceutical manufacturing facility databases and regulatory inspection records
• Validation through 3PL service pricing, warehouse capacity utilization data, and pharmaceutical outsourcing contract values
• Forecasting calibrated against biopharmaceutical pipeline projections, clinical trial activity, and cold chain investment announcements
• Company-level revenue triangulation using annual reports, investor presentations, and logistics division disclosures